Obesity Pipeline Review, H1 2018 – ResearchAndMarkets.com

The “Obesity
– Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s

Obesity – Pipeline Review, H1 2018, provides comprehensive information
on the therapeutics under development for Obesity (Metabolic Disorders),
complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press

The Obesity (Metabolic Disorders) pipeline guide also reviews of key
players involved in therapeutic development for Obesity and features
dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Filing rejected/Withdrawn, Phase III, Phase
II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages
are 1, 5, 18, 28, 1, 120, 32 and 2 respectively. Similarly, the
Universities portfolio in Phase I, Preclinical and Discovery stages
comprises 1, 53 and 10 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/research/j59j34/obesity_pipeline?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618006145/en/